(PharmaNewsWire.Com, December 01, 2017 ) The report "Flow Cytometry Market by Technology (Cell & Bead-Based), Products (Analyzer, Sorter, Reagents & Consumables & Software), Application (Research & Clinical) & End User (Commercial Organization, Hospital & Clinical Testing Labs) - Global Forecasts to 2021", The flow cytometry market is expected to reach USD 4.93 Billion by 2021 from USD 3.14 Billion in 2016, at a CAGR of 9.4% between 2016 and 2021.
Browse 106 market data Tables and 35 Figures spread through 185 Pages and in-depth TOC on "Flow Cytometry Market by Technology (Cell & Bead-Based), Products (Analyzer, Sorter, Reagents & Consumables & Software), Application (Research & Clinical) & End User (Commercial Organization, Hospital & Clinical Testing Labs) - Global Forecasts to 2021"
Early buyers will receive 10% customization on reports. Technological advancements in flow cytometry instruments, increasing use of flow cytometry in clinical trials, launch of new reagents for specific applications like diagnostics & drug discovery, development of user-friendly & intuitive software, growing prevalence of cancer & HIV/AIDS, and growing adoption of flow cytometry techniques in research activities will majorly drive the flow cytometry market.
This report broadly segments the global flow cytometry market on the basis of products & services, technologies, applications, and end users. The flow cytometry market, by products & services, is segmented into reagents & consumables, flow cytometry instruments, services, software, and accessories. The flow cytometry instruments segment is further categorized into cell analyzers and cell sorters.
On the basis of technology, the global flow cytometry market is segmented into cell-based flow cytometry and bead-based flow cytometry. In 2016, the cell-based flow cytometry technology is expected to account for the largest share of the global flow cytometry market, by technology.
Based on application, the global flow cytometry market is segmented into research applications, clinical applications, and industrial applications. In 2016, the research applications segment is expected to account for the largest share of the flow cytometry market, by application. The research applications segment is further subsegmented into pharmaceutical & biotechnology (drug discovery, in vitro toxicity testing, & stem cell research), apoptosis, immunology, cell cycle analysis, cell sorting, and cell viability. The clinical applications segment is further categorized into cancer, immunodeficiency diseases, hematology, and organ transplantation.
The end users of flow cytometry market include commercial organizations, hospitals, academic institutions & medical schools, clinical testing labs, and research institutes. In 2016, the commercial organizations end-user segment is expected to account for the largest share of the flow cytometry market, by end user. This report covers the flow cytometry market across four major geographies, namely, North America, Europe, Asia-Pacific, and the Rest of the World (RoW). North America is expected to hold the largest share of this market in 2016, while Asia-Pacific is expected to grow at the highest rate during the forecast period from 2016 to 2021. Improving healthcare infrastructure, favorable government initiatives in Asia-Pacific region, and growing focus of market players on the Asia-Pacific flow cytometry market is expected to drive the flow cytometry market in this region.
Becton, Dickinson and Company (U.S.), Beckman Coulter, Inc. (U.S.), Thermo Fisher Scientific, Inc. (U.S.), Merck KGaA (Germany), Sysmex Partec GmbH (Germany), Luminex Corporation (U.S.), Miltenyi Biotec GmbH (Germany), Bio-Rad Laboratories, Inc. (U.S.), and Sony Biotechnology (U.S.) are the key players in the global flow cytometry market.
About MarketsandMarkets™
MarketsandMarkets™ provides quantified B2B research on 30,000 high growth niche opportunities/threats which will impact 70% to 80% of worldwide companies’ revenues. Currently servicing 5000 customers worldwide including 80% of global Fortune 1000 companies as clients. Almost 75,000 top officers across eight industries worldwide approach MarketsandMarkets™ for their painpoints around revenues decisions.
Our 850 fulltime analyst and SMEs at MarketsandMarkets™ are tracking global high growth markets following the "Growth Engagement Model – GEM". The GEM aims at proactive collaboration with the clients to identify new opportunities, identify most important customers, write "Attack, avoid and defend" strategies, identify sources of incremental revenues for both the company and its competitors. MarketsandMarkets™ now coming up with 1,500 MicroQuadrants (Positioning top players across leaders, emerging companies, innovators, strategic players) annually in high growth emerging segments. MarketsandMarkets™ is determined to benefit more than 10,000 companies this year for their revenue planning and help them take their innovations/disruptions early to the market by providing them research ahead of the curve.
MarketsandMarkets’s flagship competitive intelligence and market research platform, "RT" connects over 200,000 markets and entire value chains for deeper understanding of the unmet insights along with market sizing and forecasts of niche markets.
Contact: Mr. Rohan MarketsandMarkets™ 701 Pike Street Suite 2175, Seattle, WA 98101, United States Tel: 1-888-600-6441 Email: sales@marketsandmarkets.com Connect with us on LinkedIn @ http://www.linkedin.com/company/marketsandmarkets
We are pleased to offer you this exciting, new, and entirely free professional resource. Visit our Free Biotechnology & Pharmaceuticals resource center today to browse our selection of 600+ complimentary Biotechnology & Pharmaceuticals magazines, white papers, webinars, podcasts, and more. Get popular titles including:
